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New York, New York; Nashville, Tennessee; Aalst, Belgium; Elyria, Ohio; and New Haven, ConnecticutOBJECTIVES The purpose of this study was to determine the clinical impact of non-ﬁbroatheroma
lesion phenotype in patients presenting with an acute coronary syndrome (ACS).
BACKGROUND Although ﬁbroatheromas (FAs) are known to be clinically unstable, the impact of
non-FA lesion phenotype on clinical outcomes has not been studied.
METHODS In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the
Coronary Tree) study, patients presenting with an ACS underwent 3-vessel grayscale and virtual histology
intravascular ultrasound (VH-IVUS) after successful percutaneous intervention for all culprit lesions and
were followed for 3 years. Patients were divided into those who had only the non-FA phenotype (path-
ological intimal thickening or ﬁbrotic and/or ﬁbrocalciﬁc lesions) versus those who had at least 1 non-
culprit FA.
RESULTS Among 2,880 nonculprit lesions identiﬁed by VH-IVUS, 39.8% were non-FAs (1,042 patho-
logical intimal thickening, 72 ﬁbrotic, and 33 ﬁbrocalciﬁc). Nonculprit major adverse cardiac events
(MACE) (death, myocardial infarction, or urgent rehospitalization for progressive or unstable angina)
were attributed to only 7 non-FA lesions (0.7%) versus 43 FA lesions (2.7%, p < 0.001) during 3 years
follow-up. Of 609 patients, 67 (11.0%) patients had only non-FA lesion phenotypes. Patients with only
non-FAs tended to be younger and more often female, have fewer nonculprit lesions and less overall
plaque burden and necrotic core, and fewer nonculprit lesion MACE compared with patients with at least
1 FA. In the adjusted Cox proportional hazards model, absence of a FA was a signiﬁcant predictive of a
lower 3-year nonculprit MACE rate (hazard ratio: 0.23; 95% conﬁdence interval: 0.06 to 0.95).
CONCLUSIONS Non-FA lesions were clinically stable and were rarely associated with clinical events
during 3 years of follow-up. The intermediate-term prognosis in patients presenting with ACS in whom all
nonculprit lesions are non-FAs is favorable. (PROSPECT: An Imaging Study in Patients With Unstable
Atherosclerotic Lesions; NCT00180466) (J Am Coll Cardiol Img 2013;6:908–16) ª 2013 by the American
College of Cardiology Foundation
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909laque composition is a key determinant of
the propensity for atherosclerotic lesions toA B B R E V I A T I O N S
A N D A C R O N YM S
ACS = acute coronary syndromes
CSA = cross-sectional area
EEM = external elastic
membrane
FA = ﬁbroatheroma
FFR = fractional ﬂow reserve
IQR = interquartile range
IVUS = intravascular ultrasound
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
MLA = minimal lumen area
PCI = percutaneous coronary
intervention
PIT = pathological intimal
thickening
QCA = quantitative coronary
angiography
STEMI = ST-segment elevation
myocardial infarction
TCFA = thin-cap ﬁbroatheroma
ThCFA = thick-cap
ﬁbroatheroma
irtual histologybecome unstable and result in adverse car-
diovascular events (1). Fibroatheromas (FA)
are recognized as high-risk plaques, especially thin-
cap ﬁbroatheroma (TCFA) (2,3). Conversely, non-
FA are considered to represent stable plaques,
although the relationship between non–lipid rich
plaque (NLRP) or non-FA stable lesion phenotype
and future events has not been prospectively studied.
The PROSPECT (Providing Regional Observa-
tions to Study Predictors of Events in the Coronary
Tree) study was a prospective, multicenter, natural
history study that used 3-vessel multimodality
intracoronary imaging to characterize the coronary
tree and the relationship between speciﬁc athero-
sclerotic lesions to long-term follow-up events (4).
We performed an analysis using the data from
PROSPECT to determine the clinical impact of
NLRP phenotype on long-term clinical outcomes in
patients presenting with an acute coronary syndrome
(ACS).
METHODS
Study population. The design, major inclusion and
exclusion criteria, endpoints, and deﬁnitions from the
PROSPECT study have been described in detail
(4,5). In brief, ACS patients (ST-segment elevation
myocardial infarction [STEMI] beyond 24 h, non-
STEMI, or unstable angina) underwent 3-vessel
multimodality coronary artery imaging including
quantitative coronary angiography (QCA), grayscale
intravascular ultrasound (IVUS) imaging, and radi-
ofrequency virtual histology IVUS (VH-IVUS)
(Volcano Corporation, San Diego, California) of the
proximal 6 to 8 cm of each of the 3 coronary arteries
after performance of successful and uncomplicated
percutaneous coronary intervention (PCI) of all
coronary lesions responsible for the index event and
after completion of any other planned interventions.
Patients were treated with guideline-based medical
therapy, and clinical follow-up was performed for aFrom *Columbia University Medical Center, New York, New York; yC
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institutional review board at each participating cen-
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In the present study, based on VH-IVUS anal-
ysis, subjects were divided into patients who had
only nonculprit pathological intimal thickening
(PIT) or ﬁbrotic and/or ﬁbrocalciﬁc lesions (non-
FA group) versus patients who had at least 1 non-
culprit FA (FA group).
Image analysis. All images were analyzed at inde-
pendent core laboratories (Cardiovascular Research
Foundation, New York, New York) blinded to clin-
ical outcomes. QCA of all culprit and angiographic-
ally evident nonculprit lesions (>30% visual
angiographic diameter stenosis) was per-
formed using Medis CMS software version
7.0 (Leiden, the Netherlands).
All IVUS cross sections and lesions were
co-registered to the angiographic road map
using ﬁduciary side branches for alignment.
Grayscale and VH-IVUS analyses were per-
formed using: 1) QCU-CMS (Medis) for
contouring; 2) pcVH version 2.1 (Volcano)
for contouring and data output; and 3) pro-
prietary software (qVH, Cardiovascular
Research Foundation) for segmental qualita-
tive and quantitative output (6,7). Quantita-
tive IVUS measurements for each frame
(median interslice distance of 0.40 mm)
included external elastic membrane (EEM),
lumen, and plaque and media (EEM minus
lumen) cross-sectional area (CSA), plaque
burden (plaque and media divided by EEM),
and minimal lumen area (MLA). A non-
culprit IVUS lesionhad>3 consecutive IVUS
cross sections with $40% plaque burden.
Qualitative grayscale IVUS morphology
included plaque rupture (intraplaque cavity
communicating with the lumen with an
overlying residual ﬁbrous cap fragment) (8,9).
VH-IVUS color-coded plaque components as
ﬁbrous (green), ﬁbrofatty (light green), dense cal-
cium (white), and necrotic core (red) and reported as
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r Center Aalst, OLV Hospital, Aalst, Belgium; kNorth Ohio
Ohio; {Yale University School of Medicine, New Haven,
r. Dohi has received grant support from the Banyu Life Science
consultant to Boston Scientiﬁc and Volcano Corporation. Dr.
port from Abbott Vascular, Medtronic, and St. Jude Medical.
ol-Myers Squibb/Sanoﬁ, and Eli Lilly and Company/Daiichi
tiﬁc, Covidien, Janssen Pharmaceuticals, Regado Biosciences,
r. Stone is a consultant to Boston Scientiﬁc, InfraReDx, and
onsultant to Boston Scientiﬁc. All other authors have reported
. Sherif Nagueh, MD, served as Guest Editor for this paper.
, 2013, accepted April 29, 2013.
Dohi et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 8 , 2 0 1 3
Clinical Impact of Non–Lipid Rich Lesions A U G U S T 2 0 1 3 : 9 0 8 – 1 6
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Each lesion was further classiﬁed by VH-IVUS
phenotype. A FA had >10% conﬂuent necrotic
core. If >30 of the necrotic core abutted the lumen
in >3 consecutive frames, the FA was classiﬁed as
VH-TCFA; otherwise, it was categorized as thick-
cap ﬁbroatheroma (ThCFA). PIT contained $15%
ﬁbrofatty tissue with <10% conﬂuent necrotic core
and <10% conﬂuent dense calcium. Fibrotic plaque
contained mainly ﬁbrous tissue, and ﬁbrocalciﬁc
plaque had >10% conﬂuent dense calcium (6).
Endpoints and deﬁnitions. The primary endpoint in
PROSPECT was nonculprit lesion–related major
adverse cardiac events (MACE): the composite of
cardiac death, cardiac arrest, myocardial infarction
(MI), or rehospitalization due to unstable or pro-
gressive angina. On the basis of follow-up angiog-
raphy, the primary endpoint was adjudicated by a
blinded independent clinical events committee to
previously treated versus untreated coronary seg-
ments (i.e., nonculprit lesions).
Statistical analysis. All statistical analyses were
performed using SAS version 9.2 (SAS Institute,
Cary, North Carolina). Categorical variables were
summarized using percentages and counts, andTable 1. Clinical Characteristics of the Non-FA and FA Groups
Non-FA
(n [
Age, yrs 56.0 (4
Male, % 67.2 (4
Body mass index, kg/m2 27.5 (2
Hypertension requiring medication, % 40.3 (2
Hypercholesterolemia requiring medication, % 39.3 (2
Diabetes, % 17.9 (1
Insulin dependent, % 4.5 (3
Family history of coronary artery disease, % 35.0 (2
History of cardiac intervention, % 9.0 (6
Clinical presentation: STEMI >24 h, % 29.9 (2
Clinical presentation: NSTEMI, % 68.7 (4
Estimated creatinine clearance #60 ml/min, % 9.5 (6
LDL cholesterol, mg/dl 96.2 (7
HDL cholesterol, mg/dl 38.6 (3
Triglycerides, mg/dl 120.0 (8
HbA1c, % 6.0 (5
Statins at discharge, % 73.1 (4
Statins at 3 years, % 73.2 (4
Values are median (interquartile range) or % (n/N).
FA ¼ ﬁbroatheroma; HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-density lip
myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction.compared using chi-square tests or Fischer exact tests
as appropriate. Continuous variables were presented
as medians and interquartile ranges (IQRs); com-
parisons were conducted by the Kruskal-Wallis test.
For comparison between patients with versus
without FA lesions, a model with a generalized
estimating equations approach was used to com-
pensate for any potential clustering effect of multiple
lesions in the same vessels or in the same patients and
was developed using a working correlation structure
of compound symmetry and a 2-level nested cluster
effect for patient and vessel-within-patient using the
PROC GENMOD code in SAS, with results pre-
sented as least square means with 95% conﬁdence
intervals.
Three-year outcomes are displayed as time-to-
event curves, compared by the log-rank test. Multi-
variable modeling was performed by Cox regression
model. The following variables were considered for
the multivariable model using stepwise selection:
absence of a FA, history of PCI before the current
ACS, insulin-dependent diabetes mellitus, plaque
burden at MLA site >70%, and smallest MLA
among all lesions per patient. Values of p< 0.05 were
considered statistically signiﬁcant.Group
67)
FA Group
(n [ 542) p Value
8.0–67.0) 59.0 (51.0–68.0) 0.11
5/67) 77.7 (421/542) 0.06
4.6–30.0) 28.0 (25.2–31.3) 0.29
7/67) 48.0 (258/537) 0.23
4/61) 45.8 (228/498) 0.34
2/67) 17.6 (95/540) 0.95
/67) 2.6 (14/540) 0.42
1/60) 46.8 (223/476) 0.08
/67) 10.9 (59/541) 0.63
0/67) 29.3 (159/542) 0.93
6/67) 66.6 (361/542) 0.74
/63) 9.9 (51/513) 0.92
3.2–123.4) 102.0 (80.6–129.6) 0.69
4.5–47.0) 38.6 (34.0–46.0) 0.96
8.6–188.0) 125.0 (88.6–177.1) 0.71
.5–6.4) 5.8 (5.3–6.2) 0.07
9/67) 87.4 (472/540) 0.002
1/56) 86.2 (387/449) 0.01
oprotein; LDL ¼ low-density lipoprotein; NSTEMI ¼ non–ST-segment elevation
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911RESULTS
Baseline characteristics. Of the 697 patients enrolled
in PROSPECT, 609 patients with complete 3-vessel
VH-IVUS data had at least 1 nonculprit lesion.
Overall, 542 (89.0%) patients had at least 1 FA,
whereas 67 (11.0%) patients had only non-FAs.
The baseline characteristics of these 2 groups are
shown in Table 1. There was a trend for patients in
the non-FA group to be younger, more often fe-
male, and less often have a family history of coro-
nary artery disease compared with the FA group.
Statin therapy at discharge and at 3 years was
signiﬁcantly less common in the non-FA group.
Image data on a per-patient level. The total length
of coronary arteries analyzed by QCA and volu-
metric IVUS did not differ between FA and non-FA
groups (data not shown). The number of IVUS
nonculprit lesions per patient was signiﬁcantly less in
the non-FA than in the FA group (3 [IQR: 2 to 5]
vs. 5 [IQR: 4 to 6]; p < 0.001). Patients in the
non-FA group had a smaller overall volumetric
plaque burden compared with the non-FA group
(47.2% [IQR: 44.4% to 49.6%] vs. 49.3% [IQR:Table 2. Patient-Level Quantitative Coronary Angiography and Gra
the Non-FA and FA Groups
Quantitative coronary angiography
Nonculprit lesions, n
Total length of nonculprit lesions, mm
Grayscale IVUS
Nonculprit lesions, n
Plaque rupture, %
% Plaque volume
Smallest MLA, mm2
Patients with $1 lesions with MLA #4 mm2, %
Patients with $1 lesions with plaque burden $70%, %
VH-IVUS
Total non-FA lesions per patient, n
Patients with $1 PIT, %
Patients with $1 ﬁbrotic lesion, %
Patients with $1 ﬁbrocalciﬁc lesion, %
Necrotic core volume, %
Dense calcium volume, %
Fibrous tissue volume, %
Fibrofatty volume, %
Values are median (interquartile range) or % (n/N).
FA ¼ ﬁbroatheroma; IVUS ¼ intravascular ultrasound; MLA ¼ minimal lumen area46.8% to 52.1%]; p < 0.001). The smallest MLA in
the non-FA group was larger than in the FA group
(Table 2). The frequency of patients with at least 1
lesion with a plaque rupture, an MLA <4.0 mm2, or
a plaque burden >70% was signiﬁcantly less in the
non-FA than the FA group (Table 2).
By grayscale and VH-IVUS analysis, there were
216 nonculprit lesions in the non-FA group and
2,664 lesions in the FA group. In the non-FA group,
91.2% (197 of 216) of the lesions were characterized
as PIT, and 94% (63 of 67) of patients had at least 1
PIT lesion; the rest of the lesions were either ﬁbrotic
(n ¼ 14) or ﬁbrocalciﬁc (n ¼ 5). In the FA group,
65.1% (1,773 of 2,664) of the lesions were charac-
terized as either TCFA or ThCFA; 60.5% (368 of
542) of patients had at least 1 VH-TCFA, 87.5%
(474 of 542) patients had at least 1 ThCFA, and the
rest of the lesions were either PIT (n¼ 845), ﬁbrotic
(n ¼ 58), or ﬁbrocalciﬁc (n ¼ 28).
The percentage of ﬁbrofatty tissue per patient was
signiﬁcantly larger in the non-FA than in the FA
group, whereas the percentage of necrotic core and
dense calcium was correspondingly less in the non-
FA compared with the FA group.yscale and VH-IVUS Findings of Nonculprit Lesions in
Non-FA Group
(n [ 67)
FA Group
(n [ 542) p Value
2.0 (1.0–3.0) 2.0 (1.0–4.0) 0.01
14.9 (7.2–31.7) 20.3 (8.7–37.6) 0.12
3.0 (2.0–5.0) 5.0 (4.0–6.0) <0.001
7.5 (5/67) 16.2 (88/542) 0.06
47.2 (44.4–49.6) 49.3 (46.8–52.1) <0.001
4.3 (3.6–5.6) 3.8 (3.2–4.9) 0.007
44.8 (30/67) 55.4 (300/542) 0.10
17.9 (12/67) 35.1 (190/542) 0.005
2.0 (1.0–5.0) 1.0 (0.0–3.0) <0.001
94.0 (63/67) 67.9 (368/542) <0.001
17.9 (12/67) 9.2 (50/542) 0.03
7.5 (5/67) 4.8 (26/542) 0.37
4.0 (2.4–6.0) 13.1 (8.9–18.3) <0.001
1.4 (0.7–2.4) 5.7 (3.3–9.3) <0.001
61.1 (53.5–67.4) 59.6 (55.4–63.5) 0.04
33.2 (24.6–40.8) 18.7 (14.3–25.3) <0.001
; PIT ¼ pathological intimal thickening; VH ¼ virtual histology.
Table 3. Lesion-Level Analysis of Nonculprit Lesions
Non-FA Lesions*
(PIT/Fibrotic/Fibrocalciﬁc)
(n [ 1,147)
FA Lesions*
(TCFA/ThCFA)
(n [ 1,733) p Value
All lesions
Lesion length, mm 10.7 (10.0–11.3) 19.3 (18.5–20.1) <0.001
Average EEM CSA, mm3/mm 16.0 (15.6–16.4) 16.7 (16.3–17.0) 0.004
Average lumen CSA, mm3/mm 8.5 (8.3–8.8) 8.4 (8.3–8.6) 0.45
Average plaque and media CSA, mm3/mm 7.5 (7.2–7.7) 8.2 (8.1–8.4) <0.001
MLA, mm2 7.0 (6.8–7.2) 6.3 (6.1–6.4) <0.001
Plaque burden,% 53.0 (52.5–53.5) 58.5 (57.9–59.0) <0.001
% Necrotic core CSA, % 7.2 (6.7–7.6) 18.2 (17.6–18.8) <0.001
% Dense calcium CSA, % 3.1 (2.8–3.4) 8.6 (8.1–9.2) <0.001
Lesions with MLA <4.0 mm2
Frequency, % 15.0 (172/1,147) 21.3 (369/1,733) <0.001
MLA, mm2 3.3 (3.2–3.4) 3.3 (3.3–3.4) 0.88
Plaque burden, % 57.9 (56.5–59.3) 63.1 (62.2–64.1) <0.001
NC-MACE 2.4 (4) 6.9 (23) 0.04
Lesions with plaque burden >70%
Frequency, % 3.7 (43/1,147) 12.1 (210/1,733) <0.001
MLA, mm2 4.7 (3.7–5.7) 4.4 (4.2–4.7) 0.65
Plaque burden, % 72.8 (70.8–75.1) 73.4 (71.3–75.6) 0.25
NC-MACE 2.6 (1) 10.9 (21) 0.10
Values are median (interquartile range), % (n/N), or % (n) and are given by using GEE model. *GEE least mean squares (95% conﬁdence intervals).
CSA ¼ cross-sectional area; EEM ¼ external elastic membrane; GEE ¼ generalized estimating equations; NC ¼ necrotic core; NC-MACE ¼ nonculprit major
adverse cardiac events; TCFA ¼ thin cap ﬁbroatheroma; ThCFA ¼ thick cap ﬁbroatheroma; other abbreviations as in Table 2.
Table 4. 3-Year Nonc
and FA Groups*
Nonculprit lesion–rela
Cardiac death
Cardiac arrest
MI
Q-wave MI
Non–Q-wave MI
Rehospitalization
Rehospitalization fo
Rehospitalization fo
Values are % (n). *Rates s
FA ¼ ﬁbroatheroma; MA
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912Lesion-level analysis. Overall, among the 2,880
nonculprit lesions, 1,147 (39.8%) were non-FA
(1,042 PIT, 72 ﬁbrotic, 33 ﬁbrocalciﬁc), and
1,733 (60.2%) were FA (642 VH-TCFA and 1,091
ThCFA) (Table 3).
Overall, 541 lesions had an MLA <4.0 mm2. Of
these, 31.8% (172 of 541) were non-FAs (146 PIT,ulprit Lesion-Related MACE in the Non-FA
Non-FA Group
(n [ 67)
FA Group
(n [ 542) p Value
ted MACE 3.7 (2) 12.9 (64) 0.03
0.0 (0) 0.0 (0) N/A
0.0 (0) 0.0 (0) N/A
0.0 (0) 1.3 (6) 0.39
0.0 (0) 0.5 (2) 0.62
0.0 (0) 0.8 (4) 0.48
3.7 (2) 11.9 (59) 0.04
r unstable angina 2.1 (1) 3.6 (18) 0.41
r progressive angina 1.6 (1) 9.3 (46) 0.04
hown are Kaplan-Meier estimates at 3 years.
CE ¼ major adverse cardiac events; MI ¼ myocardial infarction.18 ﬁbrotic, 8 ﬁbrocalciﬁc), and the others were VH-
TCFA (n ¼ 140) or ThCFA (n ¼ 229). Plaque
burden at the MLA site was signiﬁcantly smaller in
non-FA versus FA lesions (p < 0.001), although
the actual MLA was not different.
Overall, 253 lesions had a plaque burden >70%.
Of these, 17.0% (43 of 253) were non-FA lesions
(39 PIT, 3 ﬁbrotic, 1 ﬁbrocalciﬁc), and the others
were VH-TCFA (n ¼ 75) or ThCFA (n ¼ 135).
There were no signiﬁcant differences in plaque
burden at MLA sites comparing non-FAs versus
FAs (p ¼ 0.25).
Clinical outcomes. As shown in Table 4, the 3-year
cumulative nonculprit lesion MACE rates were
signiﬁcantly lower in the non-FA versus the FA
patient group (3.7% vs. 12.9%; p ¼ 0.03). Although
there was no occurrence of death, MI, or cardiac
arrest in the non-FA group and only 6 MIs in the
FA group, the frequency of rehospitalization for
unstable or progressive angina was signiﬁcantly
lower in the non-FA versus the FA group (3.7% vs.
11.9%; p ¼ 0.04).
The 3-year cumulative MACE rates are shown in
Figure 1. Before adjustment, the absence of any FA
was signiﬁcantly associated with a lower rate of
Figure 1. Time-to-Event Curves for Nonculprit Lesion MACE in Patients With Non-FAs
Versus FAs
Time-to-ﬁrst nonculprit lesion major adverse cardiac events (NC-MACE) was compared in
patients who had only pathological intimal thickening or ﬁbrotic and/or ﬁbrocalciﬁc lesions
(non-FA group) versus patients who had at least 1 nonculprit ﬁbroatheroma (FA group). The
3-year cumulative rates of MACE were signiﬁcantly lower in the non-FA group than in the
FA group (log-rank test: p ¼ 0.029). CI ¼ conﬁdence interval; FA ¼ ﬁbroatheroma; HR ¼
hazard ratio.
Table 5. Independent Predictors of Nonculprit MACE
Hazard Ratio
(95% CI) p Value
Absence of a ﬁbroatheroma 0.23 (0.06–0.95) 0.042
Plaque burden at minimal
lumen site >70%
1.82 (1.04–3.17) 0.035
Insulin-treated diabetes 4.56 (1.82–11.42) 0.001
CI ¼ conﬁdence interval; MACE ¼ major adverse cardiac events.
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913nonculprit lesion MACE during 3-year follow-up
(hazard ratio: 0.24; 95% conﬁdence interval: 0.06
to 0.97; p ¼ 0.045). By multivariate analysis the
absence of any FA was signiﬁcantly predictive of a
lower non-culprit lesion MACE rate during follow-
up (hazard ratio: 0.23; 95% conﬁdence interval: 0.06
to 0.95; p ¼ 0.042) (Table 5).
On a lesion-level analysis, the 3-year nonculprit
MACE rate attributed to non-FAs versus FAs was
0.7% versus 2.7%, respectively (p < 0.001). Among
untreated lesions with an MLA <4 mm2, the 3-year
nonculprit MACE rate attributed to non-FAs
versus FAs was 2.4% versus 6.9%, respectively
(p ¼ 0.04). Similarly, among untreated lesions
with a plaque burden >70%, the 3-year non-
culprit MACE rate tended to be lower in non-FA
versus FA lesion phenotypes (2.6% versus 10.9%;
p ¼ 0.10) (Table 3, Fig. 2).
D I SCUSS ION
The present PROSPECT substudy demonstrates
that nonculprit coronary lesions without the VH-
IVUS phenotype of a FA were associated with a
low rate of future cardiovascular events, lower than
lesions with a FA phenotype. Furthermore, this as-
sociation remained signiﬁcant even after adjustment
for clinically important covariates reported in the
main PROSPECT analysis. As a result, although
recurrent culprit lesion–related and unanticipated
nonculprit lesion–related events are common in pa-
tients with ACS, those patients with only untreated
non-FAs had a favorable long-term prognosis with
excellent event-free survival.
The DEFER (Deferral of Percutaneous Coronary
Intervention), FAME-I (Fractional Flow Reserve
Versus Angiography for Multivessel Evaluation),
and the registry arm of FAME-II studies have
shown that lesions with a fractional ﬂow reserve
(FFR) >0.80 remain stable with medical therapy
alone and do not need to be treated with PCI
(12–14). However, imaging studies, including the
PROSPECT study, have mainly identiﬁed high-risk
or vulnerable plaques likely to cause future events.
Yamagishi et al. (8) used grayscale IVUS to study
114 lesions in 106 patients. At a mean follow-up
of 21.6 months, 12 lesions developed an acute
occlusion, 10 of which had an echolucent zone
(8 superﬁcial and 2 deep). The PROSPECT study
demonstrated that the triad of a VH-TCFA, an
MLA <4.0 mm2, and a plaque burden >70%
predicted lesion-speciﬁc events during 3 years of
follow-up (4). Similar results were reported by the
VIVA (VH-IVUS in Vulnerable Atherosclerosis)investigators (15). Uemura et al. (16) studied
53 patients with optical coherence tomography. At
7 months of follow-up, 13 nonsigniﬁcant plaques
showed angiographic progression. Optical coherence
tomography TCFA and microchannels were associ-
ated with angiographic progression. Ohtani et al.
(17) used angioscopy to study 552 patients. At a
mean follow-up of 57.3 months, 39 patients devel-
oped an ACS. Although the maximum color grade
of the plaques was not different between ACS versus
non-ACS patients, the number of yellow plaques was
greater in ACS patients.
The current PROSPECT substudy suggests that
imaging techniques may also be useful in identifying
stable lesions and patients. Of 2,880 nonculprit
lesions identiﬁed by VH-IVUS, 1,147 were non-FA
(1,042 PIT, 72 ﬁbrotic, 33 ﬁbrocalciﬁc). The 3-year
MACE rate associated with these lesions was only
0.7%, comparable to that expected from FFR (14).
Figure 2. Event Rates in Non-FA Versus FA Lesions at a Median Follow-Up of 3.4 Years
Event rates associated in 2,880 nonculprit lesions according to the presence or absence of a minimum lumen area (MLA) <4.0 mm2 and a
plaque burden >70%, 2 of the 3 imaging predictors of nonculprit MACE reported in the PROSPECT (Providing Regional Observations to Study
Predictors of Events in the Coronary Tree) study. Abbreviations as in Figure 1.
Dohi et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 8 , 2 0 1 3
Clinical Impact of Non–Lipid Rich Lesions A U G U S T 2 0 1 3 : 9 0 8 – 1 6
914Thus, the current study suggests that deferral of
non-FAs may be safe without FFR measurement.
The converse, however, is not necessarily true; and
future studies are required to determine the event
rates in FAs (TCFAs and ThCFAs) that are FFR
positive versus negative.
In the present study, the majority of stable non-
FAs consisted of the PIT phenotype (91%). The
histopathological deﬁnition of PIT is intimal thick-
ening with extracellular lipid pools in the absence
of necrotic core formation (18). Although precise
mechanisms underlying the sequential formation of
PIT are unknown, PIT may be the morphological
and chemical bridge to more advanced plaques (19).
The temporal stability of these lesions has not been
thoroughly characterized. A serial VH-IVUS study
by Kubo et al. (20) demonstrated that 71% of PITs
remained unchanged during 12-month follow-up in
patients with stable ischemic heart disease. Thus,
maximal medical treatment of lesions with a stable
phenotype might be the key to prevent development
of more unstable phenotypes. In support of this, the
present study showed that patients with all non-FAs
remained clinically stable during 3 years of follow-
up, even when initially presenting with an ACS.
VH-IVUS phenotype classiﬁcation depends crit-
ically on subjective assessments of plaquemorphologythat may vary between observers. Wu et al. (21)
demonstrated that interobserver and intraobserver
variability were sufﬁciently low for the PIT pheno-
type (k ¼ 0.90 and k ¼ 0.92, respectively). In
addition, the variability for other stable plaque
phenotypesdﬁbrous and ﬁbrocalciﬁc lesionsdwere
also acceptable (k¼ 0.85 and k¼ 0.86; k¼ 0.81 and
k ¼ 0.83, respectively). The image analysis in
PROSPECT was performed by investigators at a
core laboratorywhowere experienced in grayscale and
VH-IVUS interpretation. Therefore, to generalize,
the reproducibility of VH-IVUS measurements may
be challenging. However, and importantly, the
implication of the current study is that <10%
necrotic core, which is an automated output of the
VH-IVUS algorithm and does not require interpre-
tation, indicates the absence of a FA and, therefore,
plaque stability.
Several prior single-center studies also demon-
strated sufﬁcient reproducibility between observers,
catheters, and repeated pullbacks (22–24). The
between-center reproducibility was recently evaluated
in 4 European IVUS centers (25). VH-IVUS mea-
surements of plaque and vessel dimensions and plaque
composition were highly correlated for the different
comparisons. Overall intraclass correlations for
ﬁbrous, ﬁbro-lipidic, necrotic core, and calciﬁed
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915volumes were 0.96, 0.94, 0.98, and 0.99, respectively.
However, signiﬁcant differences for both geometrical
and compositional measurement were seen. Of the
plaque components, ﬁbrous tissue and necrotic core
showed, on average, the highest measurement
reproducibility.
Study limitations. Our study cohort included only
nonculprit lesions in ACS patients and not culprit
plaques. The PROSPECT study enrolled a rela-
tively low-risk cohort of ACS patients in whom
PCI was successful and uncomplicated. Because
low-risk plaques tend to be dispersed throughout
the coronary tree (i.e., more distally than the
proximal 6- to 8-cm length that was imaged), the
actual prevalence of non-FA lesions might be
higher than recorded. The ability of VH-IVUS to
correctly recognize plaque composition has been
debated. Although several validation studies showed
high predictive accuracy for evaluating tissue
composition versus ex vivo human coronary arteries,
the accuracy of VH-IVUS analysis, especially
behind calcium, continues to be questioned (6,26).
In this regard, it is unclear how often there is a
deﬁnable signal compared with mostly noise behind
calcium from images obtained in vivo. In cases with
grayscale shadowing, VH-IVUS often shows the
color red, which is an artifact. We did not exclude
data behind grayscale calciﬁcation. In addition, ac-
curacy may depend on the thickness, density, andamount of calcium. In general, VH-IVUS over-
estimates, rather than underestimates, the amount
of necrotic core; as such, its speciﬁcity for stable
lesions (i.e., non-necrotic core–containing lesions)
should be high. There is also currently no speciﬁc
VH-IVUS algorithm to identify thrombus
(6,11,27). Thrombus appears green or light green
(ﬁbrotic or ﬁbrofatty plaque) depending on its age.
In the VH-IVUS analysis in the PROSPECT
study, no attempt was made to identify thrombus
and to exclude it from the overall plaque area.
Therefore, thrombus would cause a TCFA to be
misclassiﬁed as a ThCFA, and a FA to be classiﬁed
as a non-FA.CONCLUS IONS
Untreated non-FA lesions in human coronary ar-
teries in ACS patients enrolled in the PROSPECT
study remained stable during 3 years of follow-up,
rarely resulting in adverse cardiovascular events. In
particular, after successful PCI in ACS, the
intermediate-term prognosis of patients without any
untreated FAs is favorable.
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